Showing 1 - 4 of 4 Muscular Dystrophy
A prospective, multi-center, observational study of the safety, tolerability and effectiveness of SPINRAZA in adult patients with Spinal Muscular Atr

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator: Rosilyn Gborogen

Phone: 713.441.5192

The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1: END-DM1

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

Provide natural history data, biomarkers, and biological understanding of the phenotypic heterogeneity of myotonic dystrophy type 1 (DM1). ... Read more >

Neuromuscular Observational Research (MOVR) Data Hub Protocol

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >

Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maint ... Read more >

Live Chat Available